CRSP
Price
$55.96
Change
-$0.38 (-0.67%)
Updated
Aug 7 closing price
Capitalization
5.09B
82 days until earnings call
SCPH
Price
$4.59
Change
-$0.42 (-8.38%)
Updated
Aug 8, 10:53 AM (EDT)
Capitalization
264.49M
89 days until earnings call
Interact to see
Advertisement

CRSP vs SCPH

Header iconCRSP vs SCPH Comparison
Open Charts CRSP vs SCPHBanner chart's image
CRISPR Therapeutics AG
Price$55.96
Change-$0.38 (-0.67%)
Volume$1.91M
Capitalization5.09B
scPharmaceuticals
Price$4.59
Change-$0.42 (-8.38%)
Volume$200
Capitalization264.49M
CRSP vs SCPH Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. SCPH commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and SCPH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (CRSP: $55.96 vs. SCPH: $5.01)
Brand notoriety: CRSP and SCPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 55% vs. SCPH: 110%
Market capitalization -- CRSP: $5.09B vs. SCPH: $264.49M
CRSP [@Biotechnology] is valued at $5.09B. SCPH’s [@Biotechnology] market capitalization is $264.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileSCPH’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • SCPH’s FA Score: 0 green, 5 red.
According to our system of comparison, SCPH is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while SCPH’s TA Score has 4 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 5 bearish.
  • SCPH’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both CRSP and SCPH are a bad buy in the short-term.

Price Growth

CRSP (@Biotechnology) experienced а -0.53% price change this week, while SCPH (@Biotechnology) price change was -1.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

CRSP is expected to report earnings on Oct 29, 2025.

SCPH is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.09B) has a higher market cap than SCPH($264M). CRSP (42.175) and SCPH (41.525) have similar YTD gains . SCPH has higher annual earnings (EBITDA): -83.9M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. SCPH (57.5M). SCPH has less debt than CRSP: SCPH (52.4M) vs CRSP (219M). SCPH has higher revenues than CRSP: SCPH (42M) vs CRSP (35M).
CRSPSCPHCRSP / SCPH
Capitalization5.09B264M1,928%
EBITDA-455.24M-83.9M543%
Gain YTD42.17541.525102%
P/E RatioN/AN/A-
Revenue35M42M83%
Total Cash1.86B57.5M3,226%
Total Debt219M52.4M418%
FUNDAMENTALS RATINGS
CRSP vs SCPH: Fundamental Ratings
CRSP
SCPH
OUTLOOK RATING
1..100
6577
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
3936
P/E GROWTH RATING
1..100
81100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCPH's Valuation (58) in the Pharmaceuticals Major industry is in the same range as CRSP (67) in the Biotechnology industry. This means that SCPH’s stock grew similarly to CRSP’s over the last 12 months.

SCPH's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CRSP (100) in the Biotechnology industry. This means that SCPH’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to SCPH’s over the last 12 months.

SCPH's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as CRSP (39) in the Biotechnology industry. This means that SCPH’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (81) in the Biotechnology industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to SCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPSCPH
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 17 days ago
80%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 8 days ago
84%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VWINX25.82N/A
N/A
Vanguard Wellesley® Income Inv
PYVSX16.82N/A
N/A
Payden Equity Income SI
AFGGX19.60N/A
N/A
Yorktown Growth A
ALAFX97.91N/A
N/A
Alger Focus Equity A
TSVQX16.77N/A
N/A
PGIM Quant Solutions Small-Cap Val R6

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
-0.67%
RXRX - CRSP
70%
Closely correlated
-1.28%
BEAM - CRSP
70%
Closely correlated
-2.40%
NTLA - CRSP
65%
Loosely correlated
+0.88%
ABCL - CRSP
61%
Loosely correlated
+2.67%
CRBU - CRSP
60%
Loosely correlated
-3.72%
More

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with AUTL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then AUTL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
-4.75%
AUTL - SCPH
46%
Loosely correlated
+1.73%
AURA - SCPH
43%
Loosely correlated
-1.21%
BEAM - SCPH
42%
Loosely correlated
-2.40%
IPSC - SCPH
42%
Loosely correlated
-2.43%
CRSP - SCPH
41%
Loosely correlated
-0.67%
More